| Autor: |
Filipce, Ana, Naumovska, Zorica, Nestorovska, Aleksandra Kapedanovska, Sterjev, Zoran, Brezovska, Katerina, Tonic-Ribarska, Jasmina, Grozdanova, Aleksandra, Suturkova, Ljubica, Raleva, Marija |
| Zdroj: |
PRILOZI; December 2018, Vol. 39 Issue: 2-3 p97-106, 10p |
| Abstrakt: |
Atypical antipsychotic risperidone is widely used first-line monotherapy in schizophrenia and combined therapy in bipolar disorders. Therapeutic plasma concentrations of risperidone and its active moiety are directly influenced by genetic variations in metabolic CYP450 enzymes (CYP2D6 and CYP3A4/5) and transporter (ABCB1) protein and additional environmental factors. Since active metabolite 9-OH risperidone has a greater percentage of the pharmacologically active fraction and is equipotent to the parent drug risperidone, it is assumed that it contributes significantly to therapeutic and adverse effects. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
